

individual in need, thereby inhibiting neuronal degeneration at that site, with the proviso that when the individual has an autoimmune disease, said T cells are not activated against an autoimmune antigen involved in that disease.

39 (New). A method in accordance with claim 38, wherein said neuronal degeneration is that which results from an injury or disease.

40 (New). A method in accordance with claim 38, wherein NS-specific activated T cells are caused to accumulate at the site of neuronal degeneration by administering to the individual in need thereof at least one active ingredient selected from the group consisting of:

- a) NS-specific activated T cells;
- b) a NS-specific antigen;
- c) a peptide derived from a NS-specific antigen;
- d) a nucleotide sequence encoding a NS-specific antigen; and
- e) a nucleotide sequence encoding a peptide derived from a NS-specific antigen.

REMARKS

Claims 1-40 are presently pending in the present application. Claims 3, 9-15, 17, 18 and 20-37 have been withdrawn from consideration. No claims have been allowed.